Treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC).
ONTRUZANT — SAMSUNG BIOEPIS CO LTD, approved 2026-04-15 (BLA761100).
64,031 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.